<DOC>
	<DOC>NCT01470313</DOC>
	<brief_summary>This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in disease activity will also be evaluated.</brief_summary>
	<brief_title>A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus</brief_title>
	<detailed_description>The trial was terminated prematurely on Oct 15, 2013 due to a business decision. The decision to terminate the trial was not based on any clinical safety or efficacy concerns.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
	<criteria>Male and/or female subjects between the ages of 21 to 70 who have a clinical diagnosis of either discoid cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus with or without systemic lupus erythematosus prior to screening that has been confirmed by evaluation of skin biopsy sample. Active disease at both screening and baseline (Day 1) defined by a CLASI score of greater than or equal to 10. Intolerance to antimalarial therapy or more than 3 months of antimalarial therapy with disease activity. Use of greater than or equal to 20 mg or prednisone (or equivalent) within 3 months of Day 1. Signs or symptoms or relevant history of a viral, bacterial, fungal, and parasitic infection, or recent history of repeated infections Subjects with evidence of past or active tuberculosis Pregnant, planning to get pregnant, and/or lactating females or males planning to father a child within time period of the study or subsequent exclusionary period.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Safety and tolerability</keyword>
	<keyword>cutaneous lupus erythematosus</keyword>
	<keyword>efficacy</keyword>
</DOC>